There have been 33 insider transactions during the 90-day period prior to the date of this filing from the activities of 7 separate insiders all of which have been purchases and resulted in the acquisition of 4,058,250 company shares. This compares with the preceding 90-day window of time where there were 16 transactions from 2 insiders and resulted in the net acquisition of 734,232 shares.
This is less than the average level of insider transactions in the 150-company Pharmaceuticals peer group over the last 90-day period. Within the peer group activity averaged 35.0 transactions per company, and disposition of 7,132 shares on average.
SEC Story Link http://www.sec.gov/Archives/edgar/data/944809/000120919119033371/xslF345X03/doc4.xml
|2019 Estimate for Delek US Holdings Scaled Up but Q2...|
|Dillard's' Q2 Forecast Decreased but 2021 Earnings I...|
|Analysts' Scale Up Q2 and 2019 Estimates for Daimler...|
|Q3 Consensus Forecast for Citizens & Northern's ...|
|Earnings Estimate for Chevron in 2020 Scaled Down|